<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240550</url>
  </required_header>
  <id_info>
    <org_study_id>P0133</org_study_id>
    <nct_id>NCT02240550</nct_id>
  </id_info>
  <brief_title>A Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair</brief_title>
  <official_title>A Prospective, Randomized, Double-armed, Single-blinded, Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insightra Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insightra Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will be a double-armed, randomized (Blinded patients and Blinded examiner)&#xD;
      prospective study designed to collect perioperative and postoperative data to compare the QOL&#xD;
      of ProFlor vs. Lichtenstein inguinal hernia repair.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study will be to evaluate the immediate and short-term amount&#xD;
      of post-operative pain, the quality of life (QOL), as well as return to normal activities&#xD;
      (work) for the two procedures. Carolinas Comfort Scale (CCS) and Visual Analogue Score (VAS)&#xD;
      assessments will be held at regular intervals to evaluate these objectives.&#xD;
&#xD;
      The secondary objective of the study is to identify any short-term study related&#xD;
      complications/adverse events.&#xD;
&#xD;
      The follow up will be immediately post-operative, post-operative day 1, and 1, 2,and 4 weeks.&#xD;
      The first and 4th week's visits are mandatory office visits (if possible). If not available&#xD;
      for office visit, a CCS assessment will be mailed or will be conducted via phone.&#xD;
&#xD;
      Up to 50 patients may be enrolled for this study (25 per arm). A report may be generated for&#xD;
      presentation at an international meeting such as the AHS, EHS, or APHS if decided by the lead&#xD;
      investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the immediate and short-term amount of pain.</measure>
    <time_frame>1 month</time_frame>
    <description>We will evaluate the immediate and short-term amount of pain using the VAS and Carolinas Comfort Scale (CCS) assessments held at regular intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the time required for return to normal activities (work).</measure>
    <time_frame>1 month</time_frame>
    <description>We will capture the time required to return to normal activities as indicated by the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify any short-term related complication/adverse events associated with the procedures.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>ProFlor Hernia Repair System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 3-D hernia mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lichtenstein Hernia Repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using flat polypropylene mesh</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProFlor Hernia Repair System</intervention_name>
    <description>The 3-D hernia mesh will be used in the repair of your inguinal hernia.</description>
    <arm_group_label>ProFlor Hernia Repair System</arm_group_label>
    <other_name>3D mesh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lichtenstein hernia repair</intervention_name>
    <description>The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.</description>
    <arm_group_label>Lichtenstein Hernia Repair</arm_group_label>
    <other_name>Polypropylene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo routine inguinal hernia repair&#xD;
&#xD;
          -  Male and Female patients between 18 and 65 years old&#xD;
&#xD;
          -  Competent to give consent&#xD;
&#xD;
          -  Clinically relevant inguinal hernia (classification: EHS P L/M 1/2/3)&#xD;
&#xD;
          -  Defect size at operation is between 5mm and 35mm&#xD;
&#xD;
          -  Diagnosed with unilateral, direct, indirect or mixed inguinal hernia&#xD;
&#xD;
          -  Primary hernia at the operative site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of obvious local or systemic infection&#xD;
&#xD;
          -  Any previous surgery on the hernia operative site&#xD;
&#xD;
          -  Hernia is not in the inguinal area&#xD;
&#xD;
          -  Hernia is not identified as indirect or direct&#xD;
&#xD;
          -  Femoral hernias&#xD;
&#xD;
          -  Known collagen disorder&#xD;
&#xD;
          -  Presenting with unstable angina or NYHA class of IV&#xD;
&#xD;
          -  Known Pregnancy or Nursing women&#xD;
&#xD;
          -  Active drug user&#xD;
&#xD;
          -  Recurrence of a repair by any method&#xD;
&#xD;
          -  Patients with giant inguinoscrotal hernia or abdominal wall defect &gt;35 mm in diameter&#xD;
             - e.g. large direct or combined inguinal hernia type Nyhus IIIb / EHS P L/M 1/2/3&#xD;
&#xD;
          -  Immunosuppression, prednisone&gt;15 mg/day, active chemotherapy&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  Abdominal ascites&#xD;
&#xD;
          -  Skin infection in area of surgical field&#xD;
&#xD;
          -  BMI &gt;35&#xD;
&#xD;
          -  Peritoneum cannot be closed&#xD;
&#xD;
          -  Patient has a clinically relevant co-morbidity (antithrombic prophylaxis due to&#xD;
             cardiovascular pathologies, diabetes requiring insulin therapy or immunodeficiency&#xD;
             syndrome of any type)&#xD;
&#xD;
          -  Neutropenia with absolute neutrophil count (ANC)&lt;500 cells/mm3&#xD;
&#xD;
          -  Significant of life-threatening condition (e.g., endocarditis) that would confound or&#xD;
             interfere with the procedure&#xD;
&#xD;
          -  Patients that require anticoagulant monitoring with an activated partial&#xD;
             thromboplastin time (aPTT)&#xD;
&#xD;
          -  Patients unwilling to forego blood and/or blood product donation for at least 3 months&#xD;
             from initiation of first study device&#xD;
&#xD;
          -  Treatment with investigational medicinal product within 30 days before enrollment and&#xD;
             for the duration of the study&#xD;
&#xD;
          -  Investigational device present, or removed within 30 days before enrollment, or&#xD;
             presence of device-related infection&#xD;
&#xD;
          -  Patients who the investigator considers unlikely to adhere to the protocol or complete&#xD;
             the clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Healing Hands Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healing Hands Clinic</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Inguinal Hernia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

